NCT07365358Not yet recruitingPhase 4
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 15 Jan 2026
- Start date
- Mar 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Diseases
- Type 2 diabetes
- NCT number
- NCT07365358
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 200
- From Mar 2026 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening
- History of treatment with corticosteroids within 4 weeks prior to screening
Other illness
- Type 1 diabetes mellitus or secondary diabetes mellitus
- Patients with complications of severe diabetes such as proliferative diabetic retinopathy
Lab values
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Patients with abnormal laboratory test results according to the protocol
Who the study is looking for
- Over 19 years old
- Type 2 diabetes mellitus
- Patient who has been taking oral hypoglycemic agents for over 8 weeks
- Agreement with written informed consent
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kyung Hee University Hospital at Gangdong Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.